A203400 Stock Overview
Abion Inc. engages in the development of chemical and biological drugs, and vaccines in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Abion Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,990.00 |
| 52 Week High | ₩9,720.00 |
| 52 Week Low | ₩4,710.00 |
| Beta | 1.24 |
| 1 Month Change | -20.13% |
| 3 Month Change | -9.92% |
| 1 Year Change | -28.61% |
| 3 Year Change | -54.10% |
| 5 Year Change | -15.40% |
| Change since IPO | 3.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| A203400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 5.1% | -5.0% | -4.3% |
| 1Y | -28.6% | -3.5% | -1.0% |
Return vs Industry: A203400 underperformed the KR Biotechs industry which returned -3.5% over the past year.
Return vs Market: A203400 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A203400 volatility | |
|---|---|
| A203400 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A203400's share price has been volatile over the past 3 months.
Volatility Over Time: A203400's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 34 | Young-Gi Shin | abionbio.com |
Abion Inc. engages in the development of chemical and biological drugs, and vaccines in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a drug candidate for lung and stomach cancer; ABN501, a biomarker for ovarian cancer; and ABN201, a fusion protein to target cancer cells. It also develops ABN101, an interferon-beta based biological drug for the treatment of autoimmune diseases in the central nervous system.
Abion Inc. Fundamentals Summary
| A203400 fundamental statistics | |
|---|---|
| Market cap | ₩131.94b |
| Earnings (TTM) | -₩29.21b |
| Revenue (TTM) | ₩1.27b |
103.5x
P/S Ratio-4.5x
P/E RatioIs A203400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A203400 income statement (TTM) | |
|---|---|
| Revenue | ₩1.27b |
| Cost of Revenue | ₩1.33b |
| Gross Profit | -₩55.59m |
| Other Expenses | ₩29.16b |
| Earnings | -₩29.21b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33k |
| Gross Margin | -4.36% |
| Net Profit Margin | -2,292.30% |
| Debt/Equity Ratio | 148.4% |
How did A203400 perform over the long term?
See historical performance and comparison